Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx NextG UCITS ETF 21.08.2026 NXTG.LN IE00BWTNM743  170,002.00 USD   9,449,549.13   55.585  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 21.08.2026 FDNI.LN IE00BT9PVG14  425,002.00 USD   8,074,438.19   18.999  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 21.08.2026 UIGB IE00079WNSI6    5,866.00 GBP    169,129.55   28.832  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 21.08.2026 UNCU.LN IE00BD6GCF16  936,042.00 USD  47,691,034.41   50.950  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...

CLEVELAND--(BUSINESS WIRE)--Vitamix®, the brand trusted for premium blending performance for more than 100 years, today announced the launch of Vitamix Nano™, a corded personal blender that delivers the power and durability Vitamix is known for in a compact, single‑serve format. Designed for health‑focused consumers navigating busy, independent routines, Nano makes it easy to create perfectly smooth personal‑size smoothies and frozen drinks with a streamlined single‑dial interface and a smaller...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to the existing and growing body of evidence demonstrating strength in RNAi-powered transthyre...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children’s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children....

CALGARY, Alberta--(BUSINESS WIRE)--Dear Fellow Shareholders, I am writing to correct the record and explain why this upcoming meeting is about restoring disciplined governance, credible strategy, and shareholder-aligned leadership at Questor Technology Inc. (“Questor” or the “Company”). For more than 26 years, I helped build Questor’s technology, commercial relationships and market position, and as the Company’s largest shareholder, with approximately 18.62% ownership, direction or control (bas...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at ide...